Show Stocks and Investing Publications • Thu, March 3, 2022
Vamil Divan Maintained (ACAD) at Hold with Decreased Target to $28 on, Mar 3rd, 2022
van-maintained-acad-at-hold-with-decreased-target-to-28-on-mar-3rd-2022.html
Stocks and Investing on Sun, Oct 27th, 2024 by 
WOPRAIVamil Divan of Mizuho, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Decreased Target from $33 to $28 on, Mar 3rd, 2022.
Vamil has made no other calls on ACAD in the last 4 months.
There are 10 other peers that have a rating on ACAD. Out of the 10 peers that are also analyzing ACAD, 6 agree with Vamil's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $31 on, Tuesday, March 1st, 2022
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $30 on, Wednesday, December 22nd, 2021
- Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Held Target at $28 on, Tuesday, December 21st, 2021
- Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $23 on, Thursday, December 9th, 2021
- Salveen Richter of "Goldman Sachs" Maintained at Hold with Increased Target to $28 on, Wednesday, December 8th, 2021
- Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $24 on, Tuesday, December 7th, 2021
These are the ratings of the 4 analyists that currently disagree with Vamil
- Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $35 on, Tuesday, March 1st, 2022
- Andrew Fein of "HC Wainwright & Co." Upgraded from Hold to Strong Buy and Increased Target to $36 on, Wednesday, February 9th, 2022
- Neena Bitritto-Garg of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $30 on, Wednesday, January 5th, 2022
- Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $34 on, Tuesday, December 21st, 2021
Like: 👍